However, incorporating MM antigens that are not exclusive to plasma cells and myeloma cells, particularly those strongly expressed on MM cells but with lower expression on healthy cells (e.g., CD138, CD38, and SLAMF7), can offer advantages and open new possibilities [125]. This evidence concerns the gene SDC1 and Miyoshi myopathy.